Summit slips on ivonescimab's apparent interim miss in sign of investor frustration

Summit Therapeutics’ stock price {$SMMT} tumbled nearly 20% after the closing bell Thursday afternoon, following an apparent statistical miss in part of a Phase 3 trial for its cancer drug ivonescimab. In patients with a ...